The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
A more accurate, integrated risk model for pancreatic cancer included not only clinical risk factors, but also blood markers and pancreatic cancer loci from genome-wide association studies.
A woman's ability to smell differences between people with and without Parkinson's disease could someday lead to a tool to detect the condition early, according to NPR.
The multi-omics translational software developer is helping the Crohn's & Colitis Foundation validate its research into biomarkers that can predict complications requiring surgery.
The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
The new Qlucore Diagnostics software builds on the recently updated Qlucore Omics Explorer platform, initially to help clinicians diagnose and treat leukemia.
The companies are looking to model gene expression signatures to predict treatments for gastric cancer and improve patient stratification methodologies.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
